“Integrating three sophisticated laboratories in one strategic location will make our new China facility a premier destination for biopharma customers seeking high-caliber lab services to accelerate clinical research within China and on the global stage,” said Christopher Fikry, M.D., executive vice president of PPD® Laboratories. “Adding Suzhou to our central labs in Shanghai and Singapore expands the scope of our global laboratory footprint to help our customers advance drug development for patients across the world, particularly at a time when so much of our focus is on supporting trials aimed at developing vaccines and treatments for COVID-19.”
In Suzhou, the bioanalytical lab offering will include services for small molecules, biologics, and cell and gene therapies. The lab will encompass multiple technology platforms across a wide range of applications, including ligand-binding immunochemistry, liquid chromatography tandem mass spectrometry (LC-MS/MS), polymerase chain reaction (PCR) and flow cytometry. The lab will specialize in the development and validation of fully compliant robust custom assays for pharmacokinetic/pharmacodynamic (PK/PD) analyses and immunogenicity assessments in both preclinical and clinical studies.
The biomarker lab offering will include a range of services applicable across multiple regulatory compliance environments and fit-for-purpose situations. Analysis will be performed with molecular genomics, flow cytometry, ligand binding and LC-MS/MS to support both preclinical and clinical studies. PPD’s alliance with NeoGenomics Laboratories enhances its internal capabilities with extensive immunohistochemistry and molecular test menus. NeoGenomics operates an oncology-focused clinical trials testing lab in the same building as the PPD Laboratories’ central lab in Singapore and plans to establish a similar arrangement in PPD’s new Suzhou facility.
The vaccine sciences lab will provide a full range of testing services specifically designed for vaccine development trials. The lab will employ immunoassays, cell-based assays and multiplexed functional assays for vaccine efficacy and molecular assays for infectious disease monitoring. The lab’s services will span technology assessment and method development to immunogenicity and concomitant studies.
In the Asia-Pacific region, PPD also maintains a central lab in Shanghai that provides support for clinical trials being conducted in China with safety and efficacy testing, custom specimen collection kits and biorepository services. The lab provides high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development. The central lab’s innovative enterprise and information management system, the Preclarus central lab database, delivers data in real time to expedite project teams’ decision-making and help accelerate research.
In addition to the new lab in Suzhou, PPD Laboratories includes bioanalytical labs in Middleton, Wisconsin, and Richmond, Virginia; GMP (good manufacturing practices) labs in Athlone, Ireland, and Middleton; central labs in Shanghai, China, Brussels, Belgium, Highland Heights, Kentucky, and Singapore; biomarker labs in Highland Heights and Richmond; and a vaccine sciences lab in Richmond.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 25,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K, which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.